Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience, Inc. (Nasdaq: SKYE) generates news primarily through its clinical and corporate progress in metabolic health, with a focus on obesity and overweight. The company regularly issues press releases on its Phase 2a CBeyond™ trial of nimacimab, a peripherally restricted CB1-inhibiting monoclonal antibody, and on related clinical, preclinical, and corporate milestones.
Readers of the SKYE news page can expect updates on topline and extension data from the CBeyond Phase 2a study, including weight loss outcomes, body composition findings, and analyses of rebound weight gain after treatment discontinuation. Skye’s releases have highlighted the performance of nimacimab as a monotherapy and in combination with semaglutide, reporting clinically meaningful additional weight loss, changes in waist circumference, and observations about safety, gastrointestinal tolerability, and neuropsychiatric events.
The company also publishes news on preclinical diet-induced obesity models, where nimacimab has been evaluated alone and with incretin-based therapies such as tirzepatide. These announcements describe weight loss effects, post-treatment weight maintenance, and modulation of metabolic and inflammatory pathways in animal studies. In addition, Skye reports on Phase 1b data in metabolic-associated steatotic liver disease, conference presentations at scientific and medical meetings, and participation in healthcare and investor conferences.
Corporate and regulatory news items include financial results, business updates, and collaboration agreements, such as Skye’s non-exclusive global collaboration and license agreement with Halozyme Therapeutics to use ENHANZE drug delivery technology for higher-dose subcutaneous administration of nimacimab. For investors and observers tracking developments in obesity therapeutics and CB1 inhibition, the SKYE news feed offers a centralized view of Skye’s reported clinical data, preclinical research, partnering activity, and financial disclosures over time.
Skye Bioscience, Inc. (OTCQB: SKYE) announced that CEO Punit Dhillon will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference on March 09, 2021, at 7:00 AM EST. The company focuses on developing synthetic cannabinoid-derived molecules to treat glaucoma and other unmet medical needs. The presentation will be available on Skye's investor relations website. Skye's lead molecule shows potential in lowering intraocular pressure in glaucoma patients, offering a new therapeutic class.
Skye Bioscience, Inc. (OTCQB: SKYE) announced participation in three investment events in February 2021. CEO Punit Dhillon will present at the Small-Cap Growth Investor Conference on February 4 at 3:30 PM EST. He will also present at the Money Show February Virtual Expo on February 18 at 11:20 AM EST. VP Karam Takhar will present at the Benzinga Cannabis Capital Conference on February 25 at 10:40 AM EST. These presentations will provide insights into their innovative cannabinoid-derived therapies targeting glaucoma and other unmet medical needs.